Evidence built across regulation, science and real-world use
LIITA's evidence programme brings together clinical evaluation, product-specific research, peer-reviewed science, usability work and post-market surveillance. Together, these sources assess how dry microcrystalline sodium chloride can support airway hydration and mucus clearance, how BREATHOX® performs in use, and which questions require further clinical study.
A complementary antiviral rationale
A potential role in antimicrobial stewardship
Airway biophysics
Laboratory research indicates that chloride availability can support innate antiviral chemistry in epithelial cells and influence cellular conditions used in viral replication. These mechanisms provide a rationale for clinical research in acute respiratory illness. Translation into clinical antiviral efficacy remains exploratory and requires appropriately designed clinical studies.
Healthy mucus clearance depends on a well-hydrated airway surface and effective ciliary movement. When deposited sodium chloride dissolves at the airway surface, its osmotic activity can draw water towards the mucus layer, improve mucus properties and support mucociliary clearance. The magnitude and duration of the effect depend on factors such as particle deposition, exposure and timing.
Acute respiratory infections often leave clinicians with few credible treatment options when antibiotics are unlikely to help. A scientific review of the field identifies dry sodium chloride inhalation as a potential early, non-antibiotic intervention that can give patients an active form of symptom management. It may therefore help fill this therapeutic alternatives gap. When bacterial infection is clinically indicated, antibiotics remain appropriate.
From evidence to the next clinical question
LIITA's forward research programme asks whether a credible early, non-antibiotic intervention can improve symptom management and support more appropriate antibiotic use in acute respiratory infections. The approach follows a substitution model of antimicrobial stewardship: expanding the clinical toolkit with an active option when antibiotics are unlikely to provide benefit. The next step is confirmatory research with leading primary-care and academic experts.
The clinical evaluation
The BREATHOX® Clinical Evaluation Report assesses the device's intended purpose, technical performance, biological safety, clinical evidence and post-market experience. Its overall conclusion is that BREATHOX® is technically suitable for depositing dry micronised sodium chloride in the upper and lower airways and that the available evidence supports a favourable benefit-risk and tolerability profile within the evaluated use. The evaluation concludes that the intended physiological effect is to promote airway hydration, improve mucus flowability and support more efficient airway clearance. The clinical assessment has also been subject to independent review by internationally recognised respiratory expertise. Ongoing post-market clinical follow-up is used to monitor safety and performance, strengthen the evidence base and guide further validation as the clinical programme develops.
Clinical and real-world evidence
Product-specific clinical research has examined tolerability, respiratory symptoms, quality of life, mucus clearance and the course of acute respiratory illness. Considered together, the work supports continued clinical development and helps define the questions that require confirmatory study. Long-standing commercial use, post-market surveillance, vigilance review and usability evidence extend the assessment across varied users and settings. The overall safety experience is characterised primarily by mild, local and transient effects. Continued follow-up is part of LIITA's evidence plan.
What the scientific evidence suggests
We’re LIIRA CARE
Redefining respiratory self-care
Redefining respiratory self-care
LIITA Care is a late-stage biotech company dedicated to the discovery and development of novel therapies that improve the lives of consumers suffering from respiratory diseases
Our mission is to become a global provider of the future go-to solution for respiratory self-care. We do this by transforming the cough and cold category with our portfolio of clinically documented over-the-counter treatments
Our patented technology deploys NaCl microparticles in a new and consumer-friendly treatment form proven to be clinically beneficial in diseases that affect more than 80% of the world's population
Our Product Pipeline
Diversified and innovative pipeline including late-stage assets open the opportunity for position as global go-to brand for NaCl particle inhalation
The clinical evaluation
The BREATHOX® Clinical Evaluation Report assesses the device's intended purpose, technical performance, biological safety, clinical evidence and post-market experience. Its overall conclusion is that BREATHOX® is technically suitable for depositing dry micronised sodium chloride in the upper and lower airways and that the available evidence supports a favourable benefit-risk and tolerability profile within the evaluated use. The evaluation concludes that the intended physiological effect is to promote airway hydration, improve mucus flowability and support more efficient airway clearance. The clinical assessment has also been subject to independent review by internationally recognised respiratory expertise. Ongoing post-market clinical follow-up is used to monitor safety and performance, strengthen the evidence base and guide further validation as the clinical programme develops.
What the scientific evidence suggests
Airway biophysics
Healthy mucus clearance depends on a well-hydrated airway surface and effective ciliary movement. When deposited sodium chloride dissolves at the airway surface, its osmotic activity can draw water towards the mucus layer, improve mucus properties and support mucociliary clearance. The magnitude and duration of the effect depend on factors such as particle deposition, exposure and timing.
A complementary antiviral rationale
Laboratory research indicates that chloride availability can support innate antiviral chemistry in epithelial cells and influence cellular conditions used in viral replication. These mechanisms provide a rationale for clinical research in acute respiratory illness. Translation into clinical antiviral efficacy remains exploratory and requires appropriately designed clinical studies.
A potential role in antimicrobial stewardship
Acute respiratory infections often leave clinicians with few credible treatment options when antibiotics are unlikely to help. A scientific review of the field identifies dry sodium chloride inhalation as a potential early, non-antibiotic intervention that can give patients an active form of symptom management. It may therefore help fill this therapeutic alternatives gap. When bacterial infection is clinically indicated, antibiotics remain appropriate.
Clinical and real-world evidence
Product-specific clinical research has examined tolerability, respiratory symptoms, quality of life, mucus clearance and the course of acute respiratory illness. Considered together, the work supports continued clinical development and helps define the questions that require confirmatory study. Long-standing commercial use, post-market surveillance, vigilance review and usability evidence extend the assessment across varied users and settings. The overall safety experience is characterised primarily by mild, local and transient effects. Continued follow-up is part of LIITA's evidence plan.
From evidence to the next clinical question
LIITA's forward research programme asks whether a credible early, non-antibiotic intervention can improve symptom management and support more appropriate antibiotic use in acute respiratory infections. The approach follows a substitution model of antimicrobial stewardship: expanding the clinical toolkit with an active option when antibiotics are unlikely to provide benefit. The next step is confirmatory research with leading primary-care and academic experts.
Latest News
Catch up on the latest news & updates here
02 October 2020 • News Article
2025 Design Contest Winners Announced
This is your News article. It’s a great place to highlight press coverage, newsworthy stories, industry updates or useful resources for visitors.
02 October 2020 • News Article
2025 Design Contest Winners Announced
This is your News article. It’s a great place to highlight press coverage, newsworthy stories, industry updates or useful resources for visitors.
02 October 2020 • News Article
2025 Design Contest Winners Announced
This is your News article. It’s a great place to highlight press coverage, newsworthy stories, industry updates or useful resources for visitors.
Board member
Henrik Kjær Hansen
Novo Holdings
Board member
Jakob Ottesen Thiesson
Boston Consulting Group
Board member
Martin Røssberg
MR Law
CEO & Founder
Martin Ohrt
LIITA Care
CFO
Søren Kjær Henningsen
LIITA Care
Board of Directors
Management
Scientific collaboration
LIITA works with leading researchers, recognised universities, clinical environments and guideline experts to evaluate the technology using independent scientific methods. Findings from the evidence programme have been published in peer-reviewed journals and presented at leading international scientific congresses.